Cited by 48Genetic Associations and EpidemiologySchizophrenia research and treatmentBipolar Disorder and Treatment

Genetic predictors of risk and resilience in psychiatric disorders: a cross-disorder genome-wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia

Open access
McGrath, Lauren M., Cornelis, Marilyn C., Lee, Phil H., Robinson, Elise B., Duncan, Laramie E., Barnett, Jennifer H., Huang, Jie, Gerber, Gloria +4 more·2013·American Journal of Medical Genetics Part B Neuropsychiatric Genetics

Abstract

Functional impairment is one of the most enduring, intractable consequences of psychiatric disorders and is both familial and heritable. Previous studies have suggested that variation in functional impairment can be independent of symptom severity. Here we report the first genome-wide association study (GWAS) of functional impairment in the context of major mental illness. Participants of European-American descent (N = 2,246) were included from three large treatment studies of bipolar disorder (STEP-BD) (N = 765), major depressive disorder (STAR*D) (N = 1091), and schizophrenia (CATIE) (N = 390). At study entry, participants completed the SF-12, a widely used measure of health-related quality of life. We performed a GWAS and pathway analysis of the mental and physical components of health-related quality of life across diagnosis (∼1.6 million single nucleotide polymorphisms), adjusting for psychiatric symptom severity. Psychiatric symptom severity was a significant predictor of functional impairment, but it accounted for less than one-third of the variance across disorders. After controlling for diagnostic category and symptom severity, the strongest evidence of genetic association was between variants in ADAMTS16 and physical functioning (P = 5.87 × 10(-8) ). Pathway analysis did not indicate significant enrichment after correction for gene clustering and multiple testing. This study illustrates a phenotypic framework for examining genetic contributions to functional impairment across psychiatric disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajmg.b.32190

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Findings from genetic association and GWAS analyses suggest that several metzincin protease genes, including ADAMTSL3, ADAMTS12, ADAMTS-16, ADAM22, and MMP16, may confer vulnerability to schizophrenia.

    “First, converging results from several recent genetic association and genome-wide association studies indicate that genes encoding for a number of metzincin metalloproteases may represent vulnerability factors for SZ.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
McGrath, L. M., Cornelis, M. C., Lee, P. H., Robinson, E. B., Duncan, L. E., Barnett, J. H., Huang, J., Gerber, G., Sklar, P., Sullivan, P., Perlis, R. H., & Smoller, J. W.
Affiliations
  • Massachusetts General Hospital (US)
  • Harvard University (US)
  • University of Cambridge (GB)
  • Wellcome Sanger Institute (GB)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
McGrath, Lauren M.
Venue
American Journal of Medical Genetics Part B Neuropsychiatric Genetics
Publisher
Wiley
Published
2013-09-13
Volume
162
Issue
8
Pages
779-788
ISSN
  • 1552-4841 (ISSN-L)
  • 1552-485X
OpenAlex
W2087568826
Cited by
48
References
66
Citations by year
2026: 4 · 2025: 3 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 7 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 5
FWCI
3.31
Type
journal article
Language
en
Open access
Locations
  • American Journal of Medical Genetics Part B Neuropsychiatric Genetics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • Eli Lilly and Company
  • National Alliance for Research on Schizophrenia and Depression
  • National Institute of Mental Health (R01MH079799, T32MH16259, K24MH094614, T32MH016259)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
functional disability, health-related quality of life, major depressive disorder, bipolar disorder, schizophrenia, mental illness, genetic risk, resilience, ADAMTS16, physical function, symptom severity
MeSH terms
ADAMTS Proteins, Bipolar Disorder, Major Depressive Disorder, Humans, Phenotype, Risk Factors, Schizophrenia, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, ADAM Proteins, Genome-Wide Association Study, Resilience, Psychological, Genetic Loci

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review